Skip to main content

Table 1 Characteristics of 2010 incident U.S. hemodialysis patients, by vascular access at dialysis start and systemic lupus erythematosus status

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Characteristic

Overall

Vascular Access on First Dialysis:

Any

 

Catheter only

 

AVF/AVG in place

 

AVF/AVG used

 

Attributed Cause of ESRD:

SLE

Other

SLE

Other

SLE

Other

SLE

Other

N (%)

67,748 (100 %)

517 (0.8 %)

66,961 (99.2 %)

384 (0.9 %)

40,527 (99.1 %)

85 (0.6 %)

13,409 (99.4 %)

48 (0.4 %)

13,025 (99.6 %)

Demographic

         

Mean (SD) age, years

64.1 (14.9)

40.3 (15.3)a

64.3 (14.8)a

39.0 (15.0)a

64.1 (15.3)a

41.7 (15.8)a

63.8 (14.3)a

48.6 (14.2)a

65.4 (13.6)a

Female, n (%)

29,276 (43.4 %)

410 (79.3 %)a

28,866 (43.1 %)a

315 (82.0 %)a

17,951 (44.3 %)a

64 (75.3 %)a

5,675 (42.3 %)a

31 (64.6 %)b

7,785 (59.8 %)b

Race/ethnicity, %

         

 Non-Hispanic white

34,731 (51.5 %)

129 (25.0 %)a

34,602 (51.7 %)a

89 (23.2 %)a

20,813 (51.4 %) a

22 (25.9 %)a

6,644 (49.6 %)a

18 (37.5 %)

7,145 (54.9 %)

 Black

20,221 (30.0 %)

284 (54.9 %)a

19,937 (29.8 %)a

221 (57.6 %)a

11,984 (29.6 %)a

42 (49.4 %)a

4,108 (30.6 %)a

21 (43.8 %)

3,845 (29.5 %)

 Hispanic white

8,722 (12.9 %)

72 (13.9 %)a

8,650 (12.9 %)a

56 (14.6 %)a

5,526 (13.6 %)a

10 (11.8 %)a

1,829 (13.6 %)a

c

1,295 (9.9 %)

 Other

3,804 (5.6 %)

32 (6.2 %)a

3,772 (5.6 %)a

18 (4.7 %)a

2,204 (5.4 %)a

11 (12.9 %)a

828 (6.2 %)a

c

740 (5.7 %)

Insurance at dialysis start, %

         

 Private

16,546 (24.5 %)

137 (26.5 %)a

16,409 (24.5 %)a

93 (24.2 %)a

9,441 (23.3 %)a

25 (29.4 %)b

3,387 (25.3 %)b

19 (39.6 %)

3,264 (25.1 %)

 Medicare/other

27,159 (40.3 %)

104 (20.1 %)a

27,055 (40.4 %)a

67 (17.5 %)a

16,037 (39.6 %)a

21 (24.7 %)b

5,315 (39.6 %)b

16 (33.3 %)

3,581 (27.5 %)

 Medicaid

18,183 (27.0 %)

201 (38.9 %)a

17.982 (26.9 %)a

160 (41.7 %)a

10,897 (26.9 %)a

32 (37.7 %)b

3,821 (28.5 %)b

c

5,703 (43.8 %)

 None

5,590 (8.3 %)

75 (14.5 %)a

5,515 (8.2 %)a

64 (16.7 %)a

4,152 (10.3 %)a

c

886 (6.6 %)b

c

477 (3.7 %)

Clinical

         

Pre-ESRD nephrology care, %

38,937 (65.7 %)

307 (67.0 %)

38,630 (65.7 %)

200 (60.2 %)b

18,042 (52.4 %)b

64 (81.0 %)

9,034 (74.4 %)

43 (91.5 %)

11,554 (94.3 %)

Mean (SD) BMI, kg/m2

29.5 (7.9)

27.3 (7.5)a

29.5 (7.9)a

27.2 (7.5)a

29.3 (8.0)a

27.7 (6.9)a

29.9 (7.9)a

27.3 (8.3)b

29.8 (7.7)b

Congestive heart failure, %

22,893 (33.9 %)

85 (16.4 %)a

22,808 (34.1 %)a

59 (15.4 %)a

14,292 (35.3 %)a

18 (21.2 %)b

4,819 (35.9 %)b

c

3,697 (28.4 %)

Diabetes, %

38,918 (57.7 %)

62 (12.0 %)a

38,856 (58.0 %)a

44 (11.5 %)a

22,940 (56.6 %)a

12 (14.1 %)a

8,401 (62.7 %)a

c

7,515 (57.7 %)a

Peripheral vascular disease, %

9,569 (14.2 %)

21 (4.1 %)a

9,548 (14.3 %)a

16 (4.2 %)a

5,494 (13.6 %)a

c

2,267 (16.9 %)b

c

1,787 (13.7 %)b

Smoking, %

4,369 (6.5 %)

26 (5.0 %)

4,343 (6.5 %)

13 (3.4 %)b

2,645 (6.5 %)b

10 (11.8 %)

889 (6.6 %)

c

810 (6.2 %)

Transplanted within 1 year, %

853 (1.3 %)

13 (2.5 %)b

840 (1.3 %)b

c

429 (1.1 %)b

c

160 (1.2 %)

c

252 (1.9 %)

Recovered renal function within 1 year, %

1048 (1.6 %)

13 (2.5 %)

1035 (1.6 %)

11 (2.9 %)

909 (2.2 %)

c

85 (0.6 %)

c

41 (0.3 %)

  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus
  2. aP <0.001 and bP < 0.05 for SLE vs. other ESRD, by t or chi-square/Fisher’s exact test, as appropriate
  3. cNot reportable due to cell size < 10